Abstract
Clinical effects of ceftazidime (CAZ, SN 401), a new cephalosporin antibiotic, were studied in 13 patients with complicated urinary tract infections.
Ceftazidime was administered at a dose of 1.0g b. i. d. by one shot i. v. injection or drip infusion for 5 days. Ceftazidime was found to be moderate in 8 cases, the overall clinical efficacy rate being 62% in chronic complicated urinary tract infections. Bacteriologically, CAZ was active against three out of 4 strains of S. marcescens, one out of 4 strains of P. aeruginosa, one out of 2 strains of S. faecalis, and both of 2 strains of Klebsiella and of S. epidermidis. Organisms were all eradicated except for only 1 strain of S. marcescens, 3 strains of P. aeruginosa, 1 strain of S. faecalis, and 1 strain of Streptococcus. Overall bacteriological response rate was 68%.
During the treatment with CAZ, diarrhea developed in 1 case, but ceased after completion of the therapy. No other side effect was observed either subjectively or objectively.
